PMID- 31435830
OWN - NLM
STAT- MEDLINE
DCOM- 20200617
LR  - 20200617
IS  - 1865-8652 (Electronic)
IS  - 0741-238X (Print)
IS  - 0741-238X (Linking)
VI  - 36
IP  - 10
DP  - 2019 Oct
TI  - Burden of Asthma and Role of 2.5 microg Tiotropium Respimat((R)) as an Add-On Therapy: 
      A Systematic Review of Phase 2/3 Trials.
PG  - 2587-2599
LID - 10.1007/s12325-019-01062-w [doi]
AB  - INTRODUCTION: Tiotropium, a long-acting muscarinic antagonist, is approved for 
      maintenance treatment of asthma in patients at least 6 years of age in the USA. 
      We systematically reviewed published evidence on the efficacy and safety of 
      2.5 microg tiotropium Respimat((R)) add-on therapy to inhaled corticosteroid (ICS) with 
      or without additional controller medication(s) in children, adolescents, and 
      adults with asthma. METHODS: We searched PubMed from inception until October 3, 
      2018, for phase 2 and 3 randomized controlled trials (RCTs) evaluating the 
      effects of 2.5 microg tiotropium Respimat((R)) on lung function parameters in patients 
      with asthma. We extracted adjusted mean differences for lung function data and 
      adverse events (AEs) from relevant articles. RESULTS: Overall, 11 RCTs (three 
      phase 2 and eight phase 3 studies) including 3244 patients (2.5 microg tiotropium 
      Respimat((R)), n = 1642; placebo, n = 1602) met the predefined inclusion criteria. 
      Once-daily 2.5 microg tiotropium Respimat((R)) improved lung function parameters, 
      including peak and trough forced expiratory volume in 1 s and peak and trough 
      forced vital capacity, versus placebo. Overall, the safety profile of 2.5 microg 
      tiotropium Respimat((R)) was comparable to that of placebo, with the most commonly 
      reported AEs being asthma worsening, reduction in peak expiratory rate, 
      nasopharyngitis, and respiratory tract infections. CONCLUSION: On the basis of 
      the results of phase 2 and 3 studies, 2.5 microg tiotropium Respimat((R)) as add-on to 
      ICS therapy was safe and associated with consistent improvements in lung function 
      in patients with asthma of varying severities across different age groups. 
      FUNDING: Development of the manuscript was funded by Boehringer Ingelheim 
      Pharmaceuticals, Inc. (BIPI).
FAU - Mansfield, Lyndon
AU  - Mansfield L
AD  - Western Sky Medical Research, El Paso, TX, USA.
FAU - Duong-Quy, Sy
AU  - Duong-Quy S
AD  - Bio-Medical Research Center, Lam Dong Medical College, Da Lat, Vietnam.
AD  - Penn State College of Medicine, Hershey, PA, USA.
FAU - Craig, Timothy
AU  - Craig T
AD  - Penn State Allergy, Asthma and Immunology, Hershey, PA, USA. 
      tcraig@pennstatehealth.psu.edu.
LA  - eng
SI  - figshare/10.6084/m9.figshare.9334325
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20190821
PL  - United States
TA  - Adv Ther
JT  - Advances in therapy
JID - 8611864
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Muscarinic Antagonists)
RN  - XX112XZP0J (Tiotropium Bromide)
MH  - Administration, Inhalation
MH  - Adult
MH  - Asthma/*drug therapy
MH  - Bronchodilator Agents/administration & dosage/*therapeutic use
MH  - Child
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Drug Therapy, Combination
MH  - Forced Expiratory Volume/drug effects
MH  - Humans
MH  - Muscarinic Antagonists/administration & dosage/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Tiotropium Bromide/administration & dosage/*therapeutic use
PMC - PMC6822828
OTO - NOTNLM
OT  - Asthma
OT  - Step-up therapy
OT  - Tiotropium
COIS- Lyndon Mansfield has received research grants from Teva, Pearl, GlaxoSmithKline, 
      Novartis, Amphastar, Aimmune, Cipla, West-Ward, Sanofi, Chiesi, and Lupin. Sy 
      Duong-Quy has nothing to disclose. Timothy Craig has received research grants 
      from Genentech, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Regeneron, 
      and Novartis, and has received traveling grants from and is on the speakers' 
      bureau for GlaxoSmithKline and Regeneron.
EDAT- 2019/08/23 06:00
MHDA- 2020/06/18 06:00
PMCR- 2019/08/21
CRDT- 2019/08/23 06:00
PHST- 2019/06/13 00:00 [received]
PHST- 2019/08/23 06:00 [pubmed]
PHST- 2020/06/18 06:00 [medline]
PHST- 2019/08/23 06:00 [entrez]
PHST- 2019/08/21 00:00 [pmc-release]
AID - 10.1007/s12325-019-01062-w [pii]
AID - 1062 [pii]
AID - 10.1007/s12325-019-01062-w [doi]
PST - ppublish
SO  - Adv Ther. 2019 Oct;36(10):2587-2599. doi: 10.1007/s12325-019-01062-w. Epub 2019 
      Aug 21.